cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.17617782
title: 2024 SARS-CoV-2 Sequences with Diagnostic Primer/Probe Mismatch Profiles

description: A collection of 142,981 SARS-CoV-2 genomes from 2024, annotated with detailed mismatch profiles against 11 globally used diagnostic primer and probe regions. Each sequence includes a QC report identifying nucleotide variations within primer binding and probe hybridization sites, based on alignment to Wuhan-Hu-1 (NC_045512.2). Data derived from high-throughput analysis of aligned FASTA sequences and intended for use in diagnostic assay validation and variant surveillance.Sequences with ≥1 PROBE mismatch: 140,948 (98.6%)

Top 10 Most Impacted Assays (by # of sequences):
  N_gene_China: 568,780 sequences (397.8%)
  ORF1ab_China_Set1: 275,297 sequences (192.5%)
  N1_USA: 158,949 sequences (111.2%)
  E_gene_Germany: 144,591 sequences (101.1%)
  N3_USA: 10,445 sequences (7.3%)
  RdRp_Germany: 6,788 sequences (4.7%)
  N2_USA: 2,217 sequences (1.6%)
  N_gene_Japan: 2,204 sequences (1.5%)
  N_gene_Thailand: 1,949 sequences (1.4%)
  N_gene_HongKong: 1,936 sequences (1.4%)

Top 10 Most Mutated Primer/Probe Regions:
  N_gene_China_forward (forward): 434,349 mutations
  E_gene_Germany_forward (forward): 144,387 mutations
  N1_USA_probe (probe): 141,012 mutations
  ORF1ab_China_Set1_forward (forward): 140,561 mutations
  ORF1ab_China_Set1_probe (probe): 134,458 mutations
  N_gene_China_reverse (reverse): 133,763 mutations
  N1_USA_forward (forward): 17,063 mutations
  N3_USA_probe (probe): 8,144 mutations
  RdRp_Germany_forward (forward): 6,352 mutations
  N3_USA_forward (forward): 1,281 mutations

Top 15 Most Frequently Mutated Genomic Positions:
  Position 28881: 141,598 mutations
  Position 28883: 140,394 mutations
  Position 28882: 140,352 mutations
  Position 15714: 140,080 mutations
  Position 28311: 139,897 mutations
  Position 26270: 139,666 mutations
  Position 15756: 133,601 mutations
  Position 28958: 133,143 mutations
  Position 28884: 11,377 mutations
  Position 28291: 11,223 mutations
  Position 28714: 6,368 mutations
  Position 15451: 6,139 mutations
  Position 28297: 5,261 mutations
  Position 26275: 4,593 mutations
  Position 28344: 702 mutations

Distribution of # Assays Impacted per Sequence:
  0 assays (fully intact): 155 (0.1%)
  1 assays: 523 (0.4%)
  2 assays: 1,564 (1.1%)
  3 assays: 2,477 (1.7%)
  4 assays: 116,072 (81.2%)
  5 assays: 20,219 (14.1%)
  6 assays: 1,796 (1.3%)
  7 assays: 171 (0.1%)
  8 assays: 4 (0.0%)

Data Processed by: TahirHB@Hotmail.Com
DOI: 10.15468/dl.pgfqt3
title: Occurrence Download

description: A dataset containing 1118 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "TaxonKey is Zygophyllum"
 ]
}

 The dataset includes 1118 records from 29 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038441-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.z2p5cc
title: Occurrence Download

description: A dataset containing 1413 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Sphacelotheca",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1413 records from 78 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038442-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.zx5vv9
title: Occurrence Download

description: A dataset containing 840 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Farysia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 840 records from 75 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038443-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.692ghk
title: Occurrence Download

description: A dataset containing 1305 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Cintractia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1305 records from 63 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038444-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17621930
title: Synthetic Audio Event

description: Synthetic audio events created as indicated in DESED dataset (https://project.inria.fr/desed/) but modifying as necessary to create isolated events, with or without coupling, multiple events of the same type with and without coupling, and multiples of different classes with and without coupling.
DOI: 10.5281/zenodo.17621931
title: Synthetic Audio Event

description: Synthetic audio events created as indicated in DESED dataset (https://project.inria.fr/desed/) but modifying as necessary to create isolated events, with or without coupling, multiple events of the same type with and without coupling, and multiples of different classes with and without coupling.
DOI: 10.15468/dl.kqbbjn
title: Occurrence Download

description: A dataset containing 1040 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Limnoperna fortunei"
 ]
}

 The dataset includes 1040 records from 53 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038445-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17627024
title: Data cuestionario Blockchain and Performance Operation
DOI: 10.5281/zenodo.17627025
title: Data cuestionario Blockchain and Performance Operation
DOI: 10.15468/dl.scsjny
title: Occurrence Download

description: A dataset containing 238 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Bauerago",
 "HasCoordinate is true"
 ]
}

 The dataset includes 238 records from 25 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038446-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6bphug
title: Occurrence Download

description: A dataset containing 5633 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Sporisorium",
 "HasCoordinate is true"
 ]
}

 The dataset includes 5633 records from 101 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038447-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jgw6dg
title: Occurrence Download

description: A dataset containing 76 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Dendrobium chrysotoxum"
 ]
}

 The dataset includes 76 records from 19 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0038448-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29477569
title: Preoperative cryoneurolysis for peri- and postoperative pain in total knee arthroplasty: a systematic review and pooled analysis

description: Cryoneurolysis is seeing increased implementation in total knee arthroplasty (TKA), providing postoperative analgesia through preoperative cryoneurolysis of peripheral nerves. Thus, we are conducting this systematic review and meta-analysis to determine cryoneurolysis' efficacy in providing analgesia and improvements in recovery times for patients undergoing TKA. We conducted a comprehensive search using five databases including PubMed, Cochrane Library, Web of Science, Embase, and Scopus. The screened articles were assessed for inclusion of primary outcomes: pain scores before nerve cryoablation, peri- and post-operative pain scores in TKA, length of pain relief, patient demographics, and type of pain score employed. The Higgins I<sup>2</sup> test served to discern the degree of heterogeneity between included studies. Cohen’s d was utilized to interpret the pooled effect size of the studies. Our search yielded six articles that met our inclusion criteria. The overall effect size illustrated a d = 1.468 (95% CI: 1.084–1.851; <i>p</i> &lt; 0.001) for the Visual Analog Score (VAS), Numerical Rating Score (NRS), and Patient-Reported Outcomes Measurement Information System (PROMIS) pain subscore. Each individual study possessed a large effect size. Our comprehensive review and meta-analysis indicated that cryoneurolysis provides effective pain management, providing TKA patients with significant pain reduction for 6–12 weeks post-surgery. Furthermore, improvements were observed in patient-centered outcomes: mobility, return to routine activities, and overall satisfaction. Future studies should be conducted to determine the long-term efficacy of cryoneurolysis and the appropriate timing and duration of cryoneurolysis to maximize its analgesic abilities.  www.crd.york.ac.uk/prospero identifier is CRD42024542005 Cryoneurolysis is a procedure in which a nerve is cut by utilizing extremely cold temperatures. By cutting the nerve that serves to conduct pain signals from the knee, this procedure can potentially serve to provide sustained pain relief during and after total knee arthroplasties. Additionally, this procedure has been shown to reduce the amount of opioid pain medications needed by patients after surgery and improve their physical rehabilitation.
DOI: 10.6084/m9.figshare.29477569.v1
title: Preoperative cryoneurolysis for peri- and postoperative pain in total knee arthroplasty: a systematic review and pooled analysis

description: Cryoneurolysis is seeing increased implementation in total knee arthroplasty (TKA), providing postoperative analgesia through preoperative cryoneurolysis of peripheral nerves. Thus, we are conducting this systematic review and meta-analysis to determine cryoneurolysis' efficacy in providing analgesia and improvements in recovery times for patients undergoing TKA. We conducted a comprehensive search using five databases including PubMed, Cochrane Library, Web of Science, Embase, and Scopus. The screened articles were assessed for inclusion of primary outcomes: pain scores before nerve cryoablation, peri- and post-operative pain scores in TKA, length of pain relief, patient demographics, and type of pain score employed. The Higgins I<sup>2</sup> test served to discern the degree of heterogeneity between included studies. Cohen’s d was utilized to interpret the pooled effect size of the studies. Our search yielded six articles that met our inclusion criteria. The overall effect size illustrated a d = 1.468 (95% CI: 1.084–1.851; <i>p</i> &lt; 0.001) for the Visual Analog Score (VAS), Numerical Rating Score (NRS), and Patient-Reported Outcomes Measurement Information System (PROMIS) pain subscore. Each individual study possessed a large effect size. Our comprehensive review and meta-analysis indicated that cryoneurolysis provides effective pain management, providing TKA patients with significant pain reduction for 6–12 weeks post-surgery. Furthermore, improvements were observed in patient-centered outcomes: mobility, return to routine activities, and overall satisfaction. Future studies should be conducted to determine the long-term efficacy of cryoneurolysis and the appropriate timing and duration of cryoneurolysis to maximize its analgesic abilities.  www.crd.york.ac.uk/prospero identifier is CRD42024542005 Cryoneurolysis is a procedure in which a nerve is cut by utilizing extremely cold temperatures. By cutting the nerve that serves to conduct pain signals from the knee, this procedure can potentially serve to provide sustained pain relief during and after total knee arthroplasties. Additionally, this procedure has been shown to reduce the amount of opioid pain medications needed by patients after surgery and improve their physical rehabilitation.
DOI: 10.6084/m9.figshare.29483759
title: Effect of coenzyme Q10 on post-extraction tissue healing in wisdom tooth Surgery: double-blind randomized clinical trial

description: This study primarily aimed to evaluate the efficacy of Coenzyme Q10 supplementation in improving post-extraction tissue healing and, secondarily, its effects on reducing temporomandibular disorders (TMD), dry socket and enhancing quality of life following wisdom tooth extraction. This parallel randomized, double-blind, placebo-controlled trial included 70 participants, randomly assigned to receive either CoQ10 or placebo. The primary outcome was tissue healing, measured by clinical assessments on days 7, 14 and 30 post-surgeries; alongside secondary outcomes including the occurrence of TMD and dry socket occurrence. Additional secondary outcomes included physical and psychological recovery, assessed using the 36-item short form survey (SF36) and the 12-item general health questionnaire (GHQ12), which measure psychological distress and health-related quality of life. On day 7, the CoQ10 group showed a significant 45% improvement in tissue healing, compared to its counterpart and by day 14, showed a 55% improvement. TMD occurred in 12% of the CoQ10 group vs. 30% in the placebo group; and dry socket was 6% in the CoQ10 group vs. 18% in the placebo group. Coenzyme Q10 supplementation significantly accelerates tissue healing, reduces TMD and dry socket incidence and improves physical and mental health outcomes following wisdom tooth extraction. ClinicalTrials.gov [registration number NCT06452134] Improved Recovery Following Wisdom Tooth Removal Using Coenzyme Q10 This study looked at whether a daily Coenzyme Q10 supplement may help patients heal faster and lower typical problems following wisdom teeth removal. Two groups – randomly split from 70 patients – were formed. One group received a placebo; another took 100 mg of Coenzyme Q10 daily for 30 days. Following surgery, researchers examined recovery at 7, 14, and 30 days. They also noted difficulties including dry socket – a painful condition in which the blood clot in the tooth socket dissolves – and jaw joint abnormalities – temporomandibular disorder, or TMD. Furthermore, the study gauged general mental health as well as physical healing using straight forward questionnaires. With fewer cases of dry socket and TMD compared to the placebo group, the findings revealed that patients using Coenzyme Q10 healed their tissues faster. They also reported higher ratings for emotional well-being and physical functioning. These results suggest that Coenzyme Q10 not only accelerates healing but also improves overall recovery and quality of life following the wisdom tooth extraction. All things considered, Coenzyme Q10 seems to be a safe and efficient addition to assist in faster healing following wisdom teeth extraction and help to lower problems.
DOI: 10.6084/m9.figshare.29483759.v1
title: Effect of coenzyme Q10 on post-extraction tissue healing in wisdom tooth Surgery: double-blind randomized clinical trial

description: This study primarily aimed to evaluate the efficacy of Coenzyme Q10 supplementation in improving post-extraction tissue healing and, secondarily, its effects on reducing temporomandibular disorders (TMD), dry socket and enhancing quality of life following wisdom tooth extraction. This parallel randomized, double-blind, placebo-controlled trial included 70 participants, randomly assigned to receive either CoQ10 or placebo. The primary outcome was tissue healing, measured by clinical assessments on days 7, 14 and 30 post-surgeries; alongside secondary outcomes including the occurrence of TMD and dry socket occurrence. Additional secondary outcomes included physical and psychological recovery, assessed using the 36-item short form survey (SF36) and the 12-item general health questionnaire (GHQ12), which measure psychological distress and health-related quality of life. On day 7, the CoQ10 group showed a significant 45% improvement in tissue healing, compared to its counterpart and by day 14, showed a 55% improvement. TMD occurred in 12% of the CoQ10 group vs. 30% in the placebo group; and dry socket was 6% in the CoQ10 group vs. 18% in the placebo group. Coenzyme Q10 supplementation significantly accelerates tissue healing, reduces TMD and dry socket incidence and improves physical and mental health outcomes following wisdom tooth extraction. ClinicalTrials.gov [registration number NCT06452134] Improved Recovery Following Wisdom Tooth Removal Using Coenzyme Q10 This study looked at whether a daily Coenzyme Q10 supplement may help patients heal faster and lower typical problems following wisdom teeth removal. Two groups – randomly split from 70 patients – were formed. One group received a placebo; another took 100 mg of Coenzyme Q10 daily for 30 days. Following surgery, researchers examined recovery at 7, 14, and 30 days. They also noted difficulties including dry socket – a painful condition in which the blood clot in the tooth socket dissolves – and jaw joint abnormalities – temporomandibular disorder, or TMD. Furthermore, the study gauged general mental health as well as physical healing using straight forward questionnaires. With fewer cases of dry socket and TMD compared to the placebo group, the findings revealed that patients using Coenzyme Q10 healed their tissues faster. They also reported higher ratings for emotional well-being and physical functioning. These results suggest that Coenzyme Q10 not only accelerates healing but also improves overall recovery and quality of life following the wisdom tooth extraction. All things considered, Coenzyme Q10 seems to be a safe and efficient addition to assist in faster healing following wisdom teeth extraction and help to lower problems.
DOI: 10.6084/m9.figshare.29346712
title: How treatment with SGLT2 inhibitors can help people with chronic kidney disease: a plain language summary

description: <b>What is this summary about?</b> This is a summary of an article originally published in Postgraduate Medicine. The article looked at a group of medicines called sodium-glucose cotransporter 2 (SGLT2) inhibitors that can be used to treat people with chronic kidney disease (CKD). SGLT2 inhibitors were first used to treat people with type 2 diabetes (T2D). Further research has shown that these medicines can also help to protect the kidneys and the heart in people with CKD, regardless of whether they also have T2D. This article describes how SGLT2 inhibitors can affect the body and the benefits of these medicines in people with CKD. <b>What are the key takeaways?</b> CKD is a serious health problem that affects at least 1 in 7 adults in the United States. However, around 9 out of 10 adults with CKD are not aware that they have the condition. This is because people with CKD often have no symptoms, especially in the early stages of their condition. People with CKD have a higher risk of death and heart and/or kidney complications compared with people without the condition. It is important that doctors diagnose CKD as early as possible so they can advise people about lifestyle changes and treatments that help to slow the progression of their CKD. Early diagnosis and intervention can reduce the chance that someone with CKD will die prematurely, be admitted to the hospital, or eventually need dialysis or a kidney transplant. <b>What were the main conclusions reported by the author?</b> SGLT2 inhibitors can help to slow the decline in kidney function and lower the risk of death and hospitalizations in people with CKD. Research has shown that a wide range of people with CKD could benefit from treatment with SGLT2 inhibitors.
DOI: 10.6084/m9.figshare.29346712.v1
title: How treatment with SGLT2 inhibitors can help people with chronic kidney disease: a plain language summary

description: <b>What is this summary about?</b> This is a summary of an article originally published in Postgraduate Medicine. The article looked at a group of medicines called sodium-glucose cotransporter 2 (SGLT2) inhibitors that can be used to treat people with chronic kidney disease (CKD). SGLT2 inhibitors were first used to treat people with type 2 diabetes (T2D). Further research has shown that these medicines can also help to protect the kidneys and the heart in people with CKD, regardless of whether they also have T2D. This article describes how SGLT2 inhibitors can affect the body and the benefits of these medicines in people with CKD. <b>What are the key takeaways?</b> CKD is a serious health problem that affects at least 1 in 7 adults in the United States. However, around 9 out of 10 adults with CKD are not aware that they have the condition. This is because people with CKD often have no symptoms, especially in the early stages of their condition. People with CKD have a higher risk of death and heart and/or kidney complications compared with people without the condition. It is important that doctors diagnose CKD as early as possible so they can advise people about lifestyle changes and treatments that help to slow the progression of their CKD. Early diagnosis and intervention can reduce the chance that someone with CKD will die prematurely, be admitted to the hospital, or eventually need dialysis or a kidney transplant. <b>What were the main conclusions reported by the author?</b> SGLT2 inhibitors can help to slow the decline in kidney function and lower the risk of death and hospitalizations in people with CKD. Research has shown that a wide range of people with CKD could benefit from treatment with SGLT2 inhibitors.
DOI: 10.6084/m9.figshare.28320945
title: Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis

description: To systematically review and conduct a meta-analysis of studies on peripheral magnetic stimulation (PMS) for fibromyalgia (FM) treatment. MEDLINE, EMBASE, CENTRAL, CINHAL, Web of Science, and ProQuest databases were searched from inception to July 2023 for studies in adult patients with FM treated with PMS. Studies using transcranial magnetic stimulation were excluded. Six randomized controlled trials (RCTs) (<i>n</i> = 279 patients) were identified and included in the review. PMS regimens varied, ranging from 8 to 40 min per session over 3–84 days. All studies compared PMS to a visually and physically identical sham device without magnetic fields. Most of the included studies demonstrated positive findings for PMS on pain and functional outcomes. In our meta-analysis, PMS significantly reduced pain scores within 1–3 months (mean difference −1.86 on NRS, 95% confidence interval −2.85 to −0.87, <i>p</i> = 0.0002, I<sup>2</sup> = 68%, 4 studies [154 participants], low quality of evidence), but not at ≥3 months (low quality of evidence). Minimal adverse effects were reported. Evidence for PMS use in FM is encouraging for short-term benefit. However, heterogeneous patient populations, varied PMS regimens, and limited number of studies are important limitations. Large, high-quality RCTs are needed to confirm PMS benefits and to make definitive recommendations. PROSPERO Identifier is CRD42021235164. Fibromyalgia is a long-lasting condition that causes body-wide pain. This can make everyday activities difficult. This study looked at a treatment called peripheral magnetic stimulation (PMS) to see if it could help with fibromyalgia. The results showed that PMS can reduce pain by 16% to 55% over 1–3 months. It also helps people move and feel better overall. However, some studies found no big difference between PMS and placebo treatments. Therefore, PMS might not always work. Scientists think PMS can affect brain activity and blood flow. However, it is unclear how it does this. PMS might be a useful fibromyalgia treatment. More studies are needed to confirm how best to use it.